Somerville Kurt F grew its position in Becton Dickinson and Co (NYSE:BDX) by 489.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,071 shares of the medical instruments supplier’s stock after buying an additional 7,531 shares during the quarter. Somerville Kurt F’s holdings in Becton Dickinson and were worth $2,284,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in BDX. Comerica Securities Inc. increased its position in shares of Becton Dickinson and by 31.2% in the 4th quarter. Comerica Securities Inc. now owns 2,742 shares of the medical instruments supplier’s stock valued at $618,000 after acquiring an additional 652 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Becton Dickinson and by 10.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 525,300 shares of the medical instruments supplier’s stock valued at $118,354,000 after acquiring an additional 49,738 shares during the period. Geode Capital Management LLC increased its position in shares of Becton Dickinson and by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock valued at $721,582,000 after acquiring an additional 223,215 shares during the period. CX Institutional acquired a new position in shares of Becton Dickinson and in the 1st quarter valued at $87,000. Finally, Legacy Advisors LLC acquired a new position in shares of Becton Dickinson and in the 1st quarter valued at $114,000. Institutional investors own 84.80% of the company’s stock.
NYSE:BDX traded down $3.66 during mid-day trading on Friday, hitting $248.69. The company’s stock had a trading volume of 1,166,959 shares, compared to its average volume of 816,174. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $68.07 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 1.87 and a beta of 1.11. The business’s fifty day moving average price is $250.17.
The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.24%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.
In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total value of $687,836.82. Following the sale, the executive vice president now directly owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Betty D. Larson sold 1,700 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total transaction of $382,449.00. Following the completion of the sale, the executive vice president now directly owns 11,493 shares in the company, valued at $2,585,580.21. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,154 shares of company stock worth $4,955,775. 0.12% of the stock is owned by corporate insiders.
BDX has been the topic of several research reports. Raymond James upped their target price on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research report on Friday, June 28th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday. Wells Fargo & Co cut their target price on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a research report on Monday, May 13th. KeyCorp reissued an “overweight” rating and issued a $262.00 target price (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Finally, Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and a consensus target price of $265.00.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: NASDAQ
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.